Cargando…
How I treat HER2-low advanced breast cancer
INTRODUCTION: Targeting low levels of human receptor epidermal growth factor 2 (HER2) expression has reshaped the treatment paradigm for half of the patients with advanced breast cancer. HER2-low is currently defined as a HER2 immunohistochemical expression of 1+ or 2+ without amplification by in-si...
Autores principales: | Schlam, Ilana, Tolaney, Sara M., Tarantino, Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982266/ https://www.ncbi.nlm.nih.gov/pubmed/36669993 http://dx.doi.org/10.1016/j.breast.2023.01.005 |
Ejemplares similares
-
Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer
por: Rassy, Elie, et al.
Publicado: (2022) -
Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer
por: Shastry, Mythili, et al.
Publicado: (2022) -
Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy
por: Jeong, Jae Ho, et al.
Publicado: (2022) -
Clinician's guide to targeted estrogen receptor degradation using PROTAC in patients with estrogen receptor-positive metastatic breast cancer
por: Grinshpun, Albert
Publicado: (2023) -
Antibody Drug Conjugates of Near-Infrared Photoimmunotherapy (NIR-PIT) in Breast Cancers
por: Cui, Yingshu, et al.
Publicado: (2023)